Join
Live feed
·
PRReleasevia Quantisnow
Turning Point Therapeutics Inc. logo

Turning Point Therapeutics Presents Updated Preliminary Clinical Data for Repotrectinib and Elzovantinib (TPX-0022) at 2021 AACR-NCI-EORTC Conference and Provides Regulatory Updates

ByQuantisnow·Wall Street's wire, on your screen.
TPTX· Turning Point Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TPTX (Turning Point Therapeutics Inc.) and more on Quantisnow.